The proposed Studies will examine the effects of intranasally administered long-acting insulin detemir on cognition and cerebrospinal fluid (CSF) markers of AD pathology and inflammation in persons with Alzheimer's disease (AD) or its prodrome, amnestic mild cognitive Impairment (aMCl). The rationale for these studies is derived from growing evidence that insulin contributes to multiple brain functions, and that insulin dysregulation can contribute to AD pathogenesis. Thus, therapies aimed at restoring normal insulin signaling in CNS may have beneficial effects on brain function. Intranasal administration of Insulin increases insulin signaling in brain without raising peripheral levels and causing hypoglycemia. Insulin detemir is an insulin analogue that may have better action in brain than other insulin formulations because of its albumin binding properties. We will test the therapeutic effects of intranasally-administered insulin detemir in two studies: 1) an initial dose-finding study in which participants will receive one of three doses of insulin detemir or placebo for a three week period;and 2) a four-month randomized, double-blind pilot trial comparing the effects of regular insulin, the optimal dose of insulin detemir determined in study 1, and placebo. We will test the hypothesis that treatment with intranasal Insulin or insulin detemir will improve memory and daily functioning in persons with AD/aMCI, but that greater effects will be observed for insulin detemir. Participants will also undergo lumbar puncture (LP) before and at the end of treatment to measure changes in CSF B-amyloid (AB), tau, and inflammatory markers.

Public Health Relevance

Alzheimer's disease and other dementias are growing as our population ages. The development of new treatments for these challenging diseases is critical to the health of our population. The rationale for these studies is derived from growing evidence that insulin contributes to multiple brain functions, and that insulin dysregulation can contribute to Alzheimer's disease. A better understanding of the role insulin plays in cognition may lead to new treatments and strategies for preventing dementia or delaying its onset.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005136-30
Application #
8459478
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
30
Fiscal Year
2013
Total Cost
$177,732
Indirect Cost
$28,804
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-20
Toledo, Jon B; Gopal, Pallavi; Raible, Kevin et al. (2016) Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. Acta Neuropathol 131:393-409
Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90
Brenowitz, Willa D; Hubbard, Rebecca A; Keene, C Dirk et al. (2016) Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimers Dement :
Besser, Lilah M; Alosco, Michael L; Ramirez Gomez, Liliana et al. (2016) Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition. J Neuropathol Exp Neurol 75:955-962
Crane, Paul K; Gibbons, Laura E; McCurry, Susan M et al. (2016) Importance of home study visit capacity in dementia studies. Alzheimers Dement 12:419-26
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2016) Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development. Arch Gerontol Geriatr 65:231-8
Beckelman, Brenna C; Zhou, Xueyan; Keene, C Dirk et al. (2016) Impaired Eukaryotic Elongation Factor 1A Expression in Alzheimer's Disease. Neurodegener Dis 16:39-43
Henderson, Benjamin W; Gentry, Erik G; Rush, Travis et al. (2016) Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain. J Neurochem 138:525-31
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93

Showing the most recent 10 out of 583 publications